← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors
pozelimab
L04AJ11
Forms & Strengths
- Injection: 400 mg/2 mL (200 mg/mL) solution in a single-dose vial
Adult Dosing
- CD55-deficient protein-losing enteropathy (Chaple disease): Loading dose of 30 mg/kg (up to 2000 mg) IV once, followed by weekly subcutaneous maintenance doses based on body weight
Pediatric Dosing
- CD55-deficient protein-losing enteropathy (Chaple disease) in patients 1 year of age and older: Weight-based IV loading dose followed by weekly subcutaneous maintenance dosing
Indications
- Treatment of CD55-deficient protein-losing enteropathy (Chaple disease) in adult and pediatric patients aged 1 year and older
Mechanism of Action
- Recombinant human monoclonal IgG4 antibody that binds to complement factor C5, preventing its cleavage to C5a and C5b, thereby inhibiting terminal complement pathway activation
Contraindications
- Active Neisseria meningitidis infection
- Unresolved serious infection caused by encapsulated bacteria such as Streptococcus pneumoniae or Haemophilus influenzae
Adverse Reactions
- Upper respiratory tract infection
- Cellulitis
- Hypomagnesemia
- Hypokalemia
- Dizziness
- Serious infections (meningococcal infections)
Drug Interactions
- Immunizing with live-attenuated vaccines is not recommended during treatment
- Concomitant use with other complement inhibitors has not been studied and is generally avoided
Curated Content: Needs Vetting Before Put to Clinical Use